title: Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax.
abstract: CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer.
authors.affiliation: University of Tennessee Health Science Center, 875 Monroe Ave, Suite 112, Memphis, TN 38163, USA. smotl@utmem.edu
authors.forename: Susannah E
authors.initials: SE
authors.lastname: Motl
mesh_terms: D000951:Antigens, Neoplasm / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C464842:Canvaxin